Microplastic (MP) contamination in human tissues is an emerging environmental and clinical concern, yet its relevance to organ transplantation remains poorly understood. This study characterized MPs in kidney transplantation-associated donor tissues and examined their relationship with early postoperative blood pressure (BP) in recipients. Tissue samples, including kidney, adrenal gland, renal artery, renal vein, and ureter, were collected from 28 kidney transplant donors. MPs were extracted from each tissue and analyzed using a multimodal strategy: pyrolysis-gas chromatography-mass spectrometry for polymer quantification, laser direct infrared spectroscopy (LD-IR) for particle identification, and scanning electron microscopy (SEM) for morphological assessment. Polyethylene (PE) and polyvinyl chloride (PVC) were consistently the most abundant polymers by mass, with PE concentrations ranging from 25.7 to 98.9 μg/g and PVC from 31.2 to 65.4 μg/g across tissues. LD-IR analysis showed that kidney tissue contained 293 MP particles (6 polymer types), adrenal gland 2017 (9 polymer types), renal artery 881 (8 polymer types), renal vein 1528 (10 polymer types), and ureter 1672 (10 polymer types). MPs measuring 20-100 μm accounted for 47.1-54.9 % of its content across tissues, while 100-500 μm MPs comprised 45.1-52.9 %. Postoperative BP was assessed 15 days post-transplantation. While moderate, tissue-specific correlations between certain MP types and BP were observed (e.g., natural rubber in adrenal glands, polycarbonate in renal arteries, polypropylene in renal veins, and butadiene rubber in ureters), most associations were not statistically significant. Negative values were obtained for linear regression and FDR correction, emphasizing the preliminary nature of the results. This highlights the need for further investigation of the clinical impact of MP.
Background: Atrial fibrillation is the most common arrhythmia disease. Animal and observational studies have found a link between iron status and atrial fibrillation. However, the causal relationship between iron status and AF remains unclear. The purpose of this investigation was to use Mendelian randomization (MR) analysis, which has been widely applied to estimate the causal effect, to reveal whether systemic iron status was causally related to atrial fibrillation. Methods: Single nucleotide polymorphisms (SNPs) strongly associated (P < 5 × 10−8) with four biomarkers of systemic iron status were obtained from a genome-wide association study involving 48,972 subjects conducted by the Genetics of Iron Status consortium. Summary-level data for the genetic associations with atrial fibrillation were acquired from the AFGen (Atrial Fibrillation Genetics) consortium study (including 65,446 atrial fibrillation cases and 522,744 controls). We used a two-sample MR analysis to obtain a causal estimate and further verified credibility through sensitivity analysis. Results: Genetically instrumented serum iron [OR 1.09; 95% confidence interval (CI) 1.02–1.16; p = 0.01], ferritin [OR 1.16; 95% CI 1.02–1.33; p = 0.02], and transferrin saturation [OR 1.05; 95% CI 1.01–1.11; p = 0.01] had positive effects on atrial fibrillation. Genetically instrumented transferrin levels [OR 0.90; 95% CI 0.86–0.97; p = 0.006] were inversely correlated with atrial fibrillation. Conclusion: In conclusion, our results strongly elucidated a causal link between genetically determined higher iron status and increased risk of atrial fibrillation. This provided new ideas for the clinical prevention and treatment of atrial fibrillation.
The study investigated the causal relationships between spermidine levels and CVD risk factors using a bi-directional MR approach. Employing genetic variants from extensive GWAS datasets as IVs, the study aimed to determine whether spermidine levels can influence CVD risk factors such as blood pressure, blood glucose, and lipid profiles, and vice versa. The findings suggest a protective role of elevated spermidine levels against hypertension, elevated blood glucose, and lipid profiles (LDL-C and HDL-C). Specifically, increased spermidine levels were significantly associated with lower risk of hypertension (IVW beta = -0.0013453913, p = 0.01597648) and suppression risk of elevated blood glucose (IVW beta = -0.08061330, p = 0.02450205). Additionally, there was a notable association with lipid modulation, showing a decrease in LDL-C (IVW beta = -0.01849161, p = 0.01086728) and an increase in HDL-C (IVW beta = 0.0044608332, P = 0.01760051). Conversely, the influence of CVD risk factors on spermidine levels was minimal, with the exception that elevated blood glucose levels resulted in reduced spermidine levels. (IVW beta = -0.06714391, P = 0.01096123). These results underline the potential of spermidine as a modifiable dietary target for the prevention and management of cardiovascular diseases. Further investigations are warranted to explore the underlying biological mechanisms and the applicability of these findings in broader and diverse populations.
17 September 2025 in Journal of Hazardous Materials
Microplastics (MPs) have raised global concerns due to their widespread environmental presence and potential impacts on human health. In this study, we performed a detailed analysis of MPs in human gallbladder and bile samples using three analytical techniques: pyrolysis-gas chromatography-mass spectrometry, laser direct infrared spectroscopy (LD-IR), and scanning electron microscopy. A total of 23 samples were collected from patients undergoing surgery for gallstones or gallbladder polyps. MPs were detected in all samples, with polyethylene (PE) being the most abundant polymer. On average, PE was found at concentrations of 13.2 µg/g in gallbladder tissue and 12.9 µg/g in bile. Other identified polymers included polyvinyl chloride, polyamide 66, and polypropylene. LD-IR results showed that most particles were between 20 and 50 µm in size, accounting for approximately 71.2 % of particles in gallbladder samples and 70 % in bile samples. Using multimodal detection techniques, we characterized MPs in human gallbladder and bile, including their polymer types and particle sizes. These findings provide foundational data for future investigations into MP-related health risks in the hepatobiliary system.
Atherosclerosis is a leading cause of cardiovascular diseases, necessitating the identification of novel therapeutic targets. By utilizing Mendelian randomization, the aim is to identify potential drug targets for the treatment of atherosclerosis. Using results from genomewide association studies and protein quantitative trait loci data, we genetically identified causal effects of levels of several circulating proteins on atherosclerosis risk, validated using multiple statistical approaches, and identified promising drug targets. These findings demonstrated promising targets worthy of further clinical study, especially lipoprotein (a) and proprotein convertase subtilisin/kexin type 9.
Background: Cardiovascular-kidney-metabolic (CKM) syndrome represents a progressive pathophysiological continuum. While clonal hematopoiesis of indeterminate potential (CHIP) is known to increase the risk of CKM disease onset and adverse prognoses, its overall and stage-specific impacts on cardiovascular mortality within the CKM framework, alongside the circulating proteomic mechanisms mediating this excess risk, remain largely unknown. Methods: Participants from the UK Biobank with available CHIP data across the CKM syndrome continuum were included. The primary outcome was cardiovascular mortality. Kaplan-Meier curves and multivariable Cox proportional hazards models were utilized to evaluate the incremental risk conferred by CHIP. Sensitivity and subgroup analyses were conducted to ascertain result robustness. Within UKB Pharma Proteomics Project (UKB-PPP), circulating proteins jointly associated with CHIP and cardiovascular mortality were identified, followed by functional enrichment and mediation analyses to elucidate the underlying mechanisms. Results: During a median follow-up of 16.5 years, 6,515 cardiovascular deaths were recorded among 288,384 participants across CKM stages 1–4. Across all varying CKM stages, individuals harboring Large CHIP exhibited a significantly higher risk of cardiovascular mortality compared to the non-CHIP group (all log-rank P < 0.05). Following multivariable adjustment, Large CHIP emerged as an independent risk factor for cardiovascular mortality (hazard ratio, 1.24; 95% confidence interval, 1.09–1.40), with subgroup analyses confirming consistent effects regardless of CKM stage or established cardiometabolic and renal diseases. Proteomic profiling, corroborated by UKB-PPP, revealed that the mechanisms driving this excess risk predominantly involve immune-inflammatory dysregulation and tissue structural remodeling. This pathway was highlighted by critical downstream mediators, including the structural component DSC2 (mediating 34.3% of the risk) and key immune-regulatory receptors such as VSIG4 (33.1%) and CD300C (29.2%). Conclusions: CHIP is an independent risk factor for cardiovascular mortality across all stages of CKM syndrome. Mechanistically, CHIP exacerbates this adverse outcome primarily by driving systemic inflammation, immune dysregulation, and aberrant tissue remodeling.